632322-61-3

Usage

Uses

Used in Pharmaceutical Industry:
1-((2'-cyanobiphenyl-4-yl)Methyl)-2-ethoxy-1H-benziMidazole-7-carboxylic acid is used as a potential pharmaceutical compound for its unique structure and functional groups, which may offer novel therapeutic properties. The presence of the benzimidazole ring, ethoxy group, and carboxylic acid may contribute to its interaction with biological targets, such as enzymes or receptors, leading to potential applications in drug development.
Used in Biochemical Research:
1-((2'-cyanobiphenyl-4-yl)Methyl)-2-ethoxy-1H-benziMidazole-7-carboxylic acid is used as a research tool in biochemical studies to explore its interactions with biological systems. Its unique structure and functional groups may provide insights into the development of new biochemical assays, screening methods, or as a starting point for the synthesis of new bioactive compounds.
Note: The specific applications and reasons for the use of 1-((2'-cyanobiphenyl-4-yl)Methyl)-2-ethoxy-1H-benziMidazole-7-carboxylic acid are not provided in the materials. The uses mentioned above are speculative based on its unique structure and functional groups, and further research is required to confirm its potential applications.

Upstream product

• 139481-41-7 ethyl 1-[(2'-cyano-[1,1']-biphenyl-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate 
• 114772-54-2 4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile 
• 136285-67-1 ethyl 2-[(2'-cyanobiphenyl-4-yl)methyl]amino-3-nitrobenzoate 
• 136285-69-3 ethyl 3-amino-2-<<(2'-cyanobiphenyl-4-yl)methyl>amino>benzoate 
• 16533-45-2 ethyl 2-carboxy-3-nitrobenzoate 
• 136285-66-0 3-nitro-phthalic acid-1-ethyl ester-2-chloride 
• 61063-11-4 2-Amino-3-nitrobenzoic acid,ethyl ester 

Downstream Products

• 632322-62-4 2-ethoxy-1-[(2'-cyanobiphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylicacid-1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester 
• 1397836-64-4 benzhydryl 1-((2'-cyanobiphenyl-4-yl)methyl)-2-ethoxy-1Hbenzo[d]imidazole-7-carboxylate 
• 1397836-62-2 benzyl 1-((2'-cyanobiphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate 
• 1397836-45-1 benzhydryl 2-ethoxy-1-((2'-(N'-hydroxycarbamimidoyl)biphe-nyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate 
• 1397836-43-9 benzyl 2-ethoxy-1-((2'-(N'-hydroxycarbamimidoyl)biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate 
• 1403474-72-5 benzyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate 

Relevant academic research and scientific papers

Synthesis, characterization of benzimidazole carboxamide derivatives as potent anaplastic lymphoma kinase inhibitor and antioxidant activity

Novel benzimidazole carboxamide derivatives have been synthesized and characterized by FTIR, NMR, and mass spectral analysis. The synthesized compounds 7a, 7d, and 7f showed excellent scavenging capacity against DPPH radical and the results are comparable with ascorbic acid. In-silico molecular docking studies exhibited compounds 7a, 7d, and 7f had a good affinity towards the active pocket and the results indicated the ability of potent and selective inhibition of anaplastic lymphoma kinase (ALK) receptor. The theoretical investigation of MEPs, HOMO, LUMO, and the energy gap of HOMO-LUMO were calculated by B3LYP/6-31G method and reactivity descriptors were also computed.

Candesartan cilexetil preparation method

The invention provides a novel candesartan cilexetil synthesizing path which comprises the steps of carrying out alkylation reaction on 2-ethoxy benzimidazole-7-alkyl formate and 4-bromomethyl-2'-cyano biphenyl, then hydrolyzing an ester group, then reacting with 1-halogenated ethyl cyclohexyl carbonate ester to obtain an intermediate of 1-[(2'-cyano biphenyl-4-yl) methyl)-2-ethoxy-1H-benzimidazole-7-alkyl carboxylate and then obtaining candesartan cilexetil through tetrazole reaction. The novel candesartan cilexetil synthesizing path disclosed by the invention can finish alkylation, hydrolysis and ester production reaction through a one-pot method and has a few synthesizing steps and simple technology; used raw materials are easy to obtain, production cost is low, three wastes are less, and greenness and environmental friendliness are realized.

CRYSTALLINE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYL 1-((2'-CYANOBIPHENYL-4-YL)METHYL)-2-ETHOXY-1H-BENZO[D]IMIDAZOLE-7-CARBOXYLATE AND A PROCESS FOR ITS PREPARATION

The present invention relates to 1-(cyclohexyloxycarbonyloxy)ethyl 1-((2'-cyanobiphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate in crystalline form and a process for its preparation, which is useful intermediate in the preparation of candesartan cilexetil. The present invention also relates to the preparation of candesartan cilexetil and pharmaceutical composition comprising candesartan cilexetil.